Utah Medical Products 3Q 2026: Revenue $8.62M, EPS $0.88 — 10-Q Summary
Utah Medical Products reported 3Q 2026 revenue of $8.62M, down 12.1% YoY, and net income of $2.79M, up 5.9% YoY. The decline was attributed to lower sales to former major customers and declining Filshie sales, while earnings were supported by lower expenses and a lower tax rate. Management expects full-year 2026 sales to decline 7%-8% from 2025, with EPS close to $3.60 per share.
How this was made
The 30-second read
Why it matters
The earnings numbers are the first public disclosure of the quarter's performance, providing fresh data for traders.
Market read
Micro‑cap earnings release with modest materiality; limited broader market impact.
What to watch
The loss of two former major customers could signal longer‑term channel risk.
Background
Utah Medical Products filed its Q3 2026 10‑Q, highlighting a revenue decline and modest earnings improvement.
Ticker impact
Q3 2026 results show revenue down 12.1% to $8.62M and EPS up to $0.88, the first filing of these numbers.
potential pressure as the market prices in weaker revenue
The earnings release is the primary source of new data; the revenue drop is material for a micro‑cap, but the scale is modest.
Market effects
Minor impact on the medical device sector as a small player reports a revenue decline.
Limited to U.S. OTC market where the stock trades.
Low
Counterpoint
Investors may view the EPS beat as a sign of resilience despite revenue weakness.
Key entities
- companyUtah Medical Products Inc.
Medical device manufacturer reporting Q3 2026 results.
